A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Exclusion Criteria

• •Comorbidities and Medical History:
• •1. Diagnosis of or current concomitant malignancy within 3 years prior to the first dose;
• •2. Presence of multiple factors affecting oral drug intake and/or absorption;
• •3. Major surgical procedures or significant traumatic injuries within 28 days prior to the first dose;
• •4. History of arterial/venous thrombotic events within 6 months prior to the first dose;
• •5. History of psychiatric drug abuse that cannot be discontinued, or psychiatric disorders;
• •6. Presence of any severe and/or uncontrolled disease in the subject.
• •Tumor-related Symptoms and Treatment:
• •1. Diagnosis of Acute Promyelocytic Leukemia (APL), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN);
• •2. Presence of leukemia central nervous system (CNS) involvement or high suspicion of CNS involvement but unable to confirm;
• •3. Subjects with extramedullary disease only in AML;
• •4. Presence of life-threatening severe leukemia-related complications;
• •Study Treatment-related:
• •1. Received live vaccines within 4 weeks prior to the first dose, or planned to receive live vaccines during the study period;
• •2. Participated in other clinical trials involving anti-tumor drugs within 4 weeks prior to the first dose.